Understanding and integrating cytoreductive nephrectomy with immune checkpoint inhibitors in the management of metastatic RCC

Cytoreductive nephrectomy became accepted as standard of care for selected patients with metastatic renal cell carcinoma (mRCC) because of improved survival observed in patients treated with cytoreductive nephrectomy in combination with interferon-& alpha; in two randomized clinical trials published in 2001. Over the past two decades, novel systemic therapies have shown higher treatment response rates and improved survival outcomes compared with interferon-& alpha;. During this rapid evolution of mRCC treatments, systemic therapies have been the primary focus of clinical trials. Results from multiple retrospective studies continue to suggest an overall survival benefit for selected patients treated with nephrectomy in combination with systemic mRCC treatments, with the notable exception of one debated clinical trial. The optimal timing for surgery is unknown, and proper patient selection remains crucial to improving surgical outcomes. As systemic therapies continue to evolve, clinicians have an increasing need to understand how to incorporate cytoreductive nephrectomy into the management of mRCC. In this Review, the authors present the history of cytoreductive nephrectomy, discuss controversial results from clinical trials and assess future perspectives about the role of surgery in the management pathway of patients with metastatic renal cell carcinoma.

Automated summary

Cytoreductive nephrectomy is accepted as standard treatment for selected patients with mRCC due to improved survival. Novel systemic therapies have shown better outcomes compared to interferon-α, but some controversial results exist. The optimal timing and patient selection for surgery need to be determined as systemic therapies continue to evolve. This review explores the history, controversial results, and future perspectives of cytoreductive nephrectomy in managing mRCC.